Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| chimeric origin | 5434 | 1350624-75-7 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Margetuximab-cmkb, a HER2/neu receptor antagonist, is a chimeric Fc-engineered IgG1 kappa monoclonal antibody. It binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 16, 2020 | FDA | MACROGENICS INC |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FD06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors |
| MeSH PA | D000970 | Antineoplastic Agents |
| FDA MoA | N0000020008 | HER2/Neu/cerbB2 Antagonists |
| FDA EPC | N0000175661 | HER2/neu Receptor Antagonist |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | indication |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Receptor tyrosine-protein kinase erbB-2 | Kinase | ANTAGONIST | Kd | 8.55 | DRUG LABEL | DRUG LABEL | |||
| Low affinity immunoglobulin gamma Fc region receptor III-A | Membrane receptor | ANTAGONIST | Kd | 7.05 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| D10446 | KEGG_DRUG |
| K911R84KEW | UNII |
| C4053695 | UMLSCUI |
| CHEBI:754997 | CHEBI |
| CHEMBL2364649 | ChEMBL_ID |
| DB14967 | DRUGBANK_ID |
| 9799 | INN_ID |
| C000617981 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8686 | IUPHAR_LIGAND_ID |
| 1144474002 | SNOMEDCT_US |
| 1144506004 | SNOMEDCT_US |
| 4040181 | VANDF |
| 4040182 | VANDF |
| 341786 | MMSL |
| 39092 | MMSL |
| d09695 | MMSL |
| 018597 | NDDF |
| 2473850 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| MARGENZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70720-022 | INJECTION, SOLUTION, CONCENTRATE | 25 mg | INTRAVENOUS | BLA | 29 sections |
| MARGENZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 74527-022 | INJECTION, SOLUTION, CONCENTRATE | 25 mg | INTRAVENOUS | BLA | 29 sections |